REGENERON PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
REGENERON PHARMACEUTICALS, INC. (REGN) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of 0.30% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-04.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-02-04
- REGENERON PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2025 was 0.30%.
- REGENERON PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2024 was -4.90%.
- REGENERON PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2023 was -4.60%.
- REGENERON PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2022 was -2.90%, a 220.83% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | 0.30% 10-K · filed 2026-02-04 | |
| 2024-12-31 | -4.90% 10-K · filed 2026-02-04 | |
| 2023-12-31 | -4.60% 10-K · filed 2026-02-04 | 4.60% 10-K · filed 2024-02-05 |
| 2022-12-31 | -2.90% 10-K · filed 2025-02-05 | 2.90% 10-K · filed 2023-02-06 |
| 2021-12-31 | 2.40% 10-K · filed 2024-02-05 | |
| 2020-12-31 | 7.60% 10-K · filed 2023-02-06 | |
| 2019-12-31 | 2.50% 10-K · filed 2022-02-07 | -2.50% 10-K · filed 2020-02-07 |
| 2018-12-31 | 2.50% 10-K · filed 2021-02-08 | |
| 2017-12-31 | -9.00% 10-K · filed 2020-02-07 | 9.00% 10-K · filed 2018-02-08 |
| 2016-12-31 | 10.90% 10-K · filed 2019-02-07 | |
| 2015-12-31 | 0.00% 10-K · filed 2018-02-08 | |
| 2014-12-31 | 0.00% 10-K · filed 2017-02-09 | |
| 2013-12-31 | 0.00% 10-K · filed 2015-02-12 | |
| 2012-12-31 | 9.30% 10-K · filed 2015-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |